Seattle Genetics appoints Chris Boerner commercial SVP
This article was originally published in Scrip
Seattle Genetics, a biotech company focused on the development and commercialisation of monoclonal antibody-based therapies for the treatment of cancer, has appointed Dr Chris Boerner senior vice-president, commercial. He replaces Bruce Seeley who is leaving the company to pursue other opportunities. Dr Boerner joined Seattle Genetics in 2010 as vice-president of marketing. Prior to that, he spent eight years at Genentech in a variety of commercial roles, including director of marketing on Avastin (bevacizumab).